NCT05030831 - Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 11, 2022

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions

ATP-Binding Cassette Subfamily C Member 6 DeficiencyPseudoxanthoma ElasticumGeneralized Arterial Calcification of Infancy

Interventions

DRUG

INZ-701

INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).

Trial Locations (2)

07724

Clinilabs, Eatontown

SE1 1YR

Richmond Pharmacology Ltd (RPL), London